This content is machine translated Atopic dermatitis: biologics Dupilumab also effective and safe in under 12-year-olds In Switzerland, the approval of the highly effective biologic Dupilumab in the indication area of atopic dermatitis has so far been limited to adult and adolescent patients aged 12 years…
View Post 3 min This content is machine translated Atopic dermatitis: JAK inhibitors Baricitinib combined with topical steroids achieves high patient benefit When topical steroid therapy alone is not sufficiently effective, patients with atopic dermatitis may benefit greatly from the additional use of the JAK inhibitor baricitinib. This is shown, among other…
View Post 4 min This content is machine translated Chronic spontaneous urticaria When antihistamines are not enough – ligelizumab soon available in addition to omalizumab? The biologic omalizumab has empirically well-documented efficacy and safety and is considered the treatment of choice in international guidelines for cases of chronic spontaneous urticaria with inadequate response to antihistamines.…
View Post 4 min This content is machine translated Atopic dermatitis Long-term efficacy of baricitinib proven In adult patients with moderate to severe atopic dermatitis, long-term therapy with the JAK inhibitor baricitinib maintained improvements achieved after 16 weeks for 68 weeks, new data show. A pooled…
View Post 2 min This content is machine translated Digital Health Neurodermatitis patients benefit from Nia App With the new cooperation between aha! Allergy Center Switzerland and Nia Health, more sufferers in Switzerland should use the award-winning app in their daily lives. The focus is on the…
View Post 3 min This content is machine translated Case series Chronic prurigo in atopic patients: successful treatment with dupilumab. A case series of patients with prurigo was published in the journal Acta Dermato Venerologica. After multiple unsuccessful previous therapies, the use of dupilumab resulted in a significant improvement in…
View Post 3 min This content is machine translated Biomarker-based stratification Prediction of the therapy response of atopic patients In the context of new targeted therapies and the goal of precision medicine, stratification of patients based on their endotype is becoming increasingly important. Using the method of “deep phenotyping,”…
View Post 5 min This content is machine translated Chronic pruritus Management of intractable pruritus – new therapeutic options available soon? Persistent itching is very stressful for those affected and can lead to enormous suffering. A careful diagnostic clarification of chronic pruritus is the basis for a goal-oriented treatment. It remains…
View Post 4 min This content is machine translated Exogenous allergic alveolitis Don’t play the bagpipes in the Jacuzzi Exogenous allergic alveolitis (EAA) is in itself a very rare disease. So when we talk about common and rare triggers of EAA, we are dealing with very small numbers of…
View Post 3 min This content is machine translated Scabies Permethrin still first choice – therapeutic success through correct application Scabies is by no means a disease of bygone days, but there is evidence of an increase in incidence in Central Europe. Children are a major source of infection, but…
View Post 3 min This content is machine translated World Neurodermatitis Day Using new system therapies in practice – the therapeutic potential is great On the occasion of World Neurodermatitis Day on September 14, 2021, the German Dermatological Society (DDG) and the professional association of German dermatologists (BVDD) pointed out the currently available highly effective…
